Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06959095 · ClinicalTrials.gov registry record · Phase 3
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)
A Phase 3 study of Pulmonary Disease, Chronic Obstructive, sponsored by GlaxoSmithKline.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 981
- Enrollment target
- 15
- Study locations
NCT06959095: Recruiting Phase 3 study of Pulmonary Disease, Chronic Obstructive, sponsored by GlaxoSmithKline.
NCT06959095 is a Phase 3 study of Pulmonary Disease, Chronic Obstructive that is actively recruiting participants, run by GlaxoSmithKline. The registered enrollment target is 981 participants, roughly in line with the 1,031-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target. The trial reports 15 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06959095, a Phase 3 study of Pulmonary Disease, Chronic Obstructive, is actively recruiting participants, sponsored by GlaxoSmithKline.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 981 participants
- Enrollment target
- 15
- Study locations
Study Summary
Depemokimab is being developed as a treatment for individuals with moderate to severe COPD. The aim of this study is to assess the efficacy and safety of depemokimab as an add-on medicine in participants with uncontrolled moderate to severe COPD with type 2 inflammation.
Primary Outcome
Moderate exacerbations are defined as clinically significant exacerbations that require treatment with oral/systemic corticosteroids and/or antibiotics. Severe exacerbations are defined as clinically significant exacerbations that require in-patient hospitalization (i.e., greater than or equal to \[\>=\] 24 hours) or result in death. The frequency of moderate/ severe exacerbations expressed as an annualized exacerbation rate will be evaluated.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Depemokimab
Study Locations (15)
Other
- GSK Investigational Site - Chengdu
- GSK Investigational Site - Guangzhou
- GSK Investigational Site - Hangzhou
- GSK Investigational Site - Jiangmen
- GSK Investigational Site - Jiangxi
- GSK Investigational Site - Mianyang
- GSK Investigational Site - Qingyuan
- GSK Investigational Site - Zigong
- GSK Investigational Site - Tokyo
Florida
- GSK Investigational Site - Loxahatchee Groves
- GSK Investigational Site - Miami
South Carolina
- GSK Investigational Site - Rock Hill
Texas
- GSK Investigational Site - Corsicana
Hunan
- GSK Investigational Site - Changsha
Sichuan
- GSK Investigational Site - Chengdu
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 981 participants |
| Start Date | 2025-06-20 |
| Est. Completion | 2029-08-20 |
| Phase | Phase 3 |
What NCT06959095 shows while recruiting
NCT06959095 is an interventional study that assigns participants to a tested intervention. The registered 981 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 1,031-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target.
The record links to 1 condition, with Pulmonary Disease, Chronic Obstructive appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06959095 lists 15 locations in 6 states (Other, Florida, South Carolina).
Frequently Asked Questions
What is clinical trial NCT06959095 about?
NCT06959095 is a clinical study titled "Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)". Depemokimab is being developed as a treatment for individuals with moderate to severe COPD. The aim of this study is to assess the efficacy and safety of depemokimab as an add-on medicine in participants with uncontrolled moderate to severe COPD with type 2 inflammation.
What is the current status of trial NCT06959095?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 981 participants. The study started on 2025-06-20. Estimated completion is 2029-08-20.
What conditions does trial NCT06959095 study?
This clinical trial studies the following conditions: Pulmonary Disease, Chronic Obstructive.
What interventions are being tested in trial NCT06959095?
The interventions under investigation include: Placebo (DRUG), Depemokimab (DRUG).
Who is sponsoring clinical trial NCT06959095?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06959095 being conducted?
This trial has 15 study locations across Florida, South Carolina, Texas, Hunan, Sichuan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Disease, Chronic Obstructive
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06959095's enrollment target sits among peer trials
981 15th of 74 higher than 60 of 74 other Pulmonary Disease, Chronic Obstructive trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pulmonary Disease, Chronic Obstructive trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
RECRUITING · Phase 3
-
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
RECRUITING · Phase 3
-
Trial to Determine Effective Aspirin Dose in COPD
RECRUITING · Phase 3
-
An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444.Study B
COMPLETED · Phase 3
-
A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium Compared With Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease
COMPLETED · Phase 3
-
Tiotropium / Respimat One-Year Study
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06989437 · 982 participants · Phase 2
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
- NCT06337097 · 980 participants · NA
STRICT - Surveillance With TRoponin During Immune Checkpoint Therapy
- NCT07070232 · 980 participants · Phase 1
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
- NCT07184931 · 980 participants · Phase 3
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI